A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion

References

• Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56:281–99.
   PubMed Web of Science ®Google Scholar
• O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126:692–99.
   PubMed Web of Science ®Google Scholar
• Li M, Hu X, Huang J. Impact of retinal vein occlusion on stroke incidence: A meta-analysis. J Am Heart Assoc. 2016;5(12):e004703(12). doi:10.1161/jaha.116.004703.
   Web of Science ®Google Scholar
• Khan Z, Almeida DR, Rahim K, Belliveau MJ, Bona M, Gale J. 10-year framingham risk in patients with retinal vein occlusion: A systematic review and meta-analysis. Can J Ophthalmol. 2013;48:40–45.e41.
   PubMed Web of Science ®Google Scholar
• Pe’er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638–45.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. Aflibercept in wet amd: specific role and optimal use. Drug Des Devel Ther. 2013;7:711–22.
   PubMed Web of Science ®Google Scholar
• Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part b claims file. Am J Ophthalmol. 2011;151:887–895.e881.
   PubMed Web of Science ®Google Scholar
• Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012;23:175–81.
   PubMed Web of Science ®Google Scholar
• Rong AJ, Swaminathan SS, Vanner EA, Parrish RK. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019. doi:10.1016/j.ajo.2019.02.038.
   Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N. 2ʹ-fluoropyrimidine rna-based aptamers to the 165-amino acid form of vascular endothelial growth factor (vegf165). Inhibition of receptor binding and vegf-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556–67.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Muzii L, Romito A, Benedetti PP. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095–103.
   PubMed Web of Science ®Google Scholar
• Lee JH, Emelogu I, Kukreja K, Ali FS, Nogueras-Gonzalez G, Lum P, Coronel E, Ross W, Raju GS, Lynch P, et al. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. Gastrointest Endosc. 2019. doi:10.1016/j.gie.2019.02.016.
   Web of Science ®Google Scholar
• Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol. 2019. doi:10.1177/1120672119832432.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Missiroli F, Ricci F, Lanzetta P. Twelve-month outcomes of intravitreal aflibercept for neovascular age-related macular degeneration: fixed versus as-needed dosing. Retina. 2018. doi:10.1097/IAE.0000000000002299.
   Web of Science ®Google Scholar
• Stewart MW. Clinical and differential utility of vegf inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012. doi:10.2147/opth.s33372.
   Google Scholar
• Chen X, Chen Y, Cai X, Zhang D, Fan L, Qiu H, Zhang B, Guo G. Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis. J Cancer Res Ther. 2017;13:869–77.
   PubMed Web of Science ®Google Scholar
• Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492–506.
   PubMedGoogle Scholar
• Shin S, Noh Y. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: A meta-analysis of randomized controlled trials. Ther Clin Risk Manag. 2018;14:833–47.
   PubMed Web of Science ®Google Scholar
• Zarbin MA. Anti-vegf agents and the risk of arteriothrombotic events. Asia Pac J Ophthalmol (Phila). 2018;7:63–67.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–i: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ (Clinical Research ed). 1994;308(6921):81–106.
   PubMed Web of Science ®Google Scholar
• Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the vibrant study. Ophthalmology. 2016;123(2):330‐336. doi:10.1016/j.ophtha.2015.09.035.
   Web of Science ®Google Scholar
• Figueroa MS. New perspectives in the approach to central retinal vein occlusion. Arch Soc Esp Oftalmol. 2015;90(Suppl 1):15–23. doi:10.1016/s0365-6691(15)30005-8.
   PubMedGoogle Scholar
• Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the copernicus study. Ophthalmology. 2014;121(7):1414–20. doi:10.1016/j.ophtha.2014.01.027.
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 galileo study. Ophthalmology. 2014;121(1):202‐208. doi:10.1016/j.ophtha.2013.08.012.
   Web of Science ®Google Scholar
• Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik JF, Stemper B, Asmus F, Rittenhouse KD, Ahlers C. Integrated results from the copernicus and galileo studies. Clin Ophthalmol. 2017;11:1533‐1540. doi:10.2147/OPTH.S140665.
   Web of Science ®Google Scholar
• Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the brighter study. Ophthalmology. 2017;124(12):1778–87. doi:10.1016/j.ophtha.2017.06.027.
   PubMed Web of Science ®Google Scholar
• Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: bravo and cruise trials. Ophthalmology. 2014;121(5):1059–66. doi:10.1016/j.ophtha.2013.11.022.
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 copernicus study. Ophthalmology. 2012;119(5):1024–32.
   PubMed Web of Science ®Google Scholar
• Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314–23.
   PubMed Web of Science ®Google Scholar
• Bennett DA. Methodology of the global and regional burden of stroke study. Neuroepidemiology. 2012;38:30–40.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, Lennartsson J, Zhu C, Qu Y, Fang C, et al. Vegf-b inhibits apoptosis via vegfr-1-mediated suppression of the expression of bh3-only protein genes in mice and rats. J Clin Invest. 2008;118(3):913–23.
   PubMed Web of Science ®Google Scholar
• Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, et al. Vascular endothelial growth factor-b acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122(17):1725–33.
   PubMed Web of Science ®Google Scholar
• Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009;116:2393–99.
   PubMed Web of Science ®Google Scholar
• Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370:204–06.
   PubMed Web of Science ®Google Scholar
• Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014;132:1317–26.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA. A phase i trial of an iv-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522–e1.
   PubMed Web of Science ®Google Scholar
• Dixon JA, Oliver SC, Olson JL, Mandava N. Vegf trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18:1573–80.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis. 2008;14:37–49.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454–59.
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19:1920–25.
   PubMed Web of Science ®Google Scholar
• Louzier V, Raffestin B, Leroux A, Branellec D, Caillaud J, Levame M, Eddahibi S, Adnot S. Role of vegf-b in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2003;284:L926–L937.
   PubMed Web of Science ®Google Scholar
• Berger AR, Cruess AF, Altomare F, Chaudhary V, Colleaux K, Greve M, Kherani A, Mandelcorn ED, Parsons H, Rhéaume MA, et al. Optimal treatment of retinal vein occlusion: canadian expert consensus. Ophthalmologica. 2015;234(1):6–25.
   PubMed Web of Science ®Google Scholar
• Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. Retinal vein occlusions preferred practice pattern((r)) guidelines. Ophthalmology. 2016;123:P182–P208.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Amoaku WM, Hykin P. The royal college of ophthalmologists guidelines on retinal vein occlusions: executive summary. Eye. 2016;30:642–642.
   PubMed Web of Science ®Google Scholar